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Mitochondrial DNA diseases are common neurological conditions caused by mutations in the
mitochondrial genome or nuclear genes responsible for its maintenance. Current treatments for
these disorders are focussed on the management of the symptoms, rather than the correction of
biochemical defects caused by the mutation. This review focuses on the molecular effects of
mutations, the symptoms they cause and current work focusing on the development of targeted
treatments for mitochondrial DNA disease.
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Mitochondria are dynamic organelles responsible for producing
the majority of ATP, the cellular unit of energy, by a process called
oxidative phosphorylation (OXPHOS). This process relies on the
transport of electrons across 4 protein complexes in the inner
mitochondrial membrane to create an electrochemical gradient.
The ﬁnal OXPHOS complex, ATP synthase, utilises this gradient to
drive the formation of ATP and H2O [1]. Mutations in mitochon-
drial DNA (mtDNA), a circular 16.6 kb intronless multi-copy
genome found within the mitochondrial matrix, can compromise
the production of ATP [2,3]. This genome encodes 13 hydrophobic
proteins that are essential subunits of OXPHOS complexes (I,III, IV
& V), along with 22 tRNAs and the 2 rRNAs essential for their
translation [4].Mitochondrial DNA mutations
Mutations of mitochondrial DNA (mtDNA) include point muta-
tions and deletions, the latter of which can arise either from a
primary mutation or a mutation in mtDNA maintenance genes
(this can also lead to mtDNA depletion) [5,6]. Pathogenic muta-
tions in mtDNA primarily affect the mt-tRNAs and protein
encoding regions and a large number of mutations have nowig. 1 – Locations of common disease causing mutations and sympto
common deletion” is shown in the centre of the genome. Abbrevi
S – Leigh syndrome, MELAS – mitochondrial encephalopathy, lacti
nd ragged red ﬁbres, MILS – maternally inherited Leigh syndrome,
S – Pearson's syndrome.been characterised. Although mtDNA has been retained through
evolution, nuclear DNA (nDNA) encodes the majority of mito-
chondrial proteins, including the transcription and replication
machinery for mtDNA. As a consequence of this, several muta-
tions of nDNA genes essential for mtDNA maintenance have been
described which subsequently cause mtDNA point mutations,
multiple deletions or mtDNA depletion [7–10]. The complex
interactions between nuclear and mitochondrial genomes and
the heterogeneity of mitochondrial disease make the develop-
ment of treatments very challenging. This mini-review describes
the characteristics of several common primary mtDNA mutations
(Fig. 1) and diseases they cause. Potential anti-genomic treat-
ments for heteroplasmic mutations and the recent advances in
this ﬁeld are also discussed.Heteroplasmy and threshold
The multi-copy nature of the mitochondrial genome leads to
complicated genetics. MtDNA mutations can be either hetero-
plasmic (where both mutated and wild type mtDNA co-exist
within the cell) or homoplasmic (only mutated species are
present). In the presence of heteroplasmy, for a mutated species
to cause a phenotypic effect, the proportion of mutated mtDNA
and wild-type mtDNA (heteroplasmy) needs to increase to a level
where wild-type mtDNA can no longer compensate for thems they cause. Point mutations are represented by arrows; the
ations: CPEO – chronic progressive external opthalmoplegia,
c acidosis, stroke-like episodes, MERRF – Myoclonic epilepsy
NARP – neurogenic weakness, ataxia and retinitis pigmentosa,
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required to cause a detectable phenotype depends on the muta-
tion type. Broadly speaking, however, single large-scale mtDNA
deletions that remove several genes generally require much lower
heteroplasmy (60%) of mutated mtDNA than tRNA point muta-
tions such as m.3243A4G mt-tRNALeu(UUR) mutation which
decreases the rate of protein translation [12], usually requiring
heteroplasmy greater than 80% [11]. Pathogenic homoplasmic
mtDNA are less common than heteroplasmic mtDNA mutations.
However, three common point mutations, m.11778G4A,
m.3460G4A and m.14484T4C which cause Leber's Hereditary
Optic Neuropathy (LHON) are often homoplasmic [13].Maternal inheritance and genetic bottleneck
MtDNA is strictly maternally transmitted; thus women with
homoplasmic mtDNA mutations transmit the mutation to their
offspring. The situation with heteroplasmic mtDNA mutations is
signiﬁcantly more complicated due to the genetic bottleneck early
in development. This bottleneck ensures that some mutations,
such as single large scale deletions, are rarely transmitted to
offspring, but for those that are transmitted, there is a wide
variation in the level of heteroplasmy in the offspring [14].MtDNA point mutations
Pathogenic mtDNA point mutations have been described in mt-
tRNAs, mt-rRNAs and protein encoding genes, causing a wide range
of diseases. The presence of a mutation in mtDNA may not
necessarily lead to the same disease in affected individuals, generat-
ing a wide clinical spectrum which often makes it hard to diagnose
the pathogenic cause of the disease without genetic testing.m.3243A4G
First described by Goto et al. in 1990, this mutation in mt-tRNALeu
(UUR) is responsible for 80% of MELAS (mitochondrial encephalo-
myopathy with lactic acidosis and stroke like episodes) cases [15].
The mutation decreases the rate of protein synthesis, thought to
be caused by the prevention of 5-taurinomethyluridine modiﬁca-
tions of the uridine wobble-position in the tRNA [12]. Other work
has also indicated that the mutation may also cause a decrease in
tRNALeu(UUR) and its aminoacylated form, and also cause dimer-
isation of the molecule [16]. The consequence of decreased
protein synthesis is a respiratory chain complex defect, which
leads to the clinical symptoms.
Although this mutation is best known for its associations with
MELAS, in fact relatively few patients with the mutation develop
this phenotype. Analysis of the UK MRC mitochondrial disease
patient cohort has shown that only 10% of patients with the
mutation develop MELAS, whereas 30% have maternally inherited
diabetes and deafness (MIDD) [17]. The study also showed that
patients can also develop a mixture of phenotypes such as
MELAS/MIDD syndrome. Interestingly 28% of patients in the
cohort had a mixture of symptoms not consistent with normally
associated clinical phenotypes. On the other end of the spectrum,
9% of m.3243A4G carriers had no clinical features [17]. This study
highlighted the phenotypic heterogeneity associated with justone mtDNA point mutation, elegantly showing the difﬁculty of
clinical diagnosis.
m.8344A4G
This mutation, found in mitochondrial mt-tRNALys, was ﬁrst
described in 1990 and is the cause of 80% of cases of MERRF
(myoclonic epilepsy with ragged red ﬁbres) [18]. Similar to the
m.3243A4G, this mtDNA mutation affects taurine modiﬁcation of
the uridine-wobble position which causes lysine misincorporation
and a decreased protein synthesis rate [19,20].
Although the biochemical effects of this mutation should be
similar to m.3242A4G, both mutations lead to OXPHOS deﬁcits;
the phenotypic consequences of the defect are generally different,
although some patients with m.8344A4G have shown MIDD like
features [21]. MERRF patients exhibit myoclonus, generalised
epilepsy and ataxia along with ragged red ﬁbres in muscle tissues.
They can also develop hearing loss, cognitive decline, peripheral
neuropathy, optic atrophy and exercise intolerance. Interestingly
the mutation has also been shown to reach near homoplasmic
levels in adipose tissue around the neck and upper back where it
leads to benign growths in the form of lipomas [22].
m.8993T4G
The pathogenic effect of this mutation is caused by a Leu 156 Arg
amino acid substitution in ATP synthase subunit 6, which is
thought to impair the synthesis of ATP. The close proximity of the
mutation to Glu 58, an amino acid which is essential for the
transfer of protons from the intermembrane space through the
complex, was thought to affect the protonation and deprotonation
of the residue, inhibiting proton transfer [23]. However, more
recently it has been shown that this mutation may in fact alter the
ability of c ring subunits to rotate [24]. Interestingly, this mutation
also creates a unique endonuclease restriction site in affected
genomes, something that has been investigated in cell models as
a potential therapy for these disorders (see below). It should also
be noted that an m.8993T4C mutation can also occur and that
this is typically associated with a milder phenotype [25].
First described in relation to NARP (neuropathy, ataxia, retinitis
pigmentosa), this mutation has more recently been reported in cases
of MILS (maternally inherited Leigh's syndrome), a disease that
occurs in early life causing respiratory abnormalities, dystonia, optic
atrophy and is usually fatal [26]. It is thought that the level of
heteroplasmy plays a major role in the phenotypic presentation
[27,28]. If a patient has between 90% and 95% heteroplasmy, they
generally show NARP symptoms; in cases with higher heteroplasmy
it is likely that the patient will have MILS phenotype [29].Large scale, single mtDNA deletions
Large-scale deletions of mtDNA are thought to occur during repair
and/or replication of the genome [30]. Single large-scale mtDNA
deletions are typically sporadic, occurring in the germline, and are
responsible for some common mitochondrial diseases, which are
discussed below. Although there is heterogeneity of single dele-
tion size, studies have shown that a number of patients have a
5 kb deletion spanning ATPase 8 to ND5 – the so called
“common deletion” nt.8467_13446del4977 [31]. Recent work
Fig. 2 – Targeted treatments for mtDNA diseases. A schematic showing the steps required for treatments to access mtDNA.
1. Treatments must be delivered to cell, either as a protein or gene. 2. Selective targeting through mitochondrial membranes.
3. Accumulation in the matrix. 4. Selective targeting of mutated genomes. The binding of three therapies to mtDNA is also shown.
SmaI endonuclease recognises the m.8993T4G mutation and introduces a double strand break; two ZFNs bind separate regions of
mtDNA, one to a mutated area, the other to wild type, enabling their FokI nucleases to interact and cleave mtDNA; TALENs behave
in a similar way to ZFPs, requiring two TALENs to bind mtDNA. However, the protein which recognises the mtDNA sequence is
longer and wraps around mtDNA.
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severity [32]. This has provided a tool to enable clinicians to
predict the progression of patients with single deletions, poten-
tially leading to better management of the diseases [32].
The clinical features associated with single large-scale mtDNA
deletion disease are varied, similar to the point mutations described
previously. The phenotypes include Pearson's syndrome which is an
early onset disease associated with sideroblastic anaemia and exo-
crine pancreatic dysfunction; Kearns Sayre Syndrome which is a
multisystem disease occurring in childhood and adolescence; and
chronic progressive opthalmoplegia which is a later onset disease
with predominantly eye muscle involvement. It is important torecognise that these symptoms represent a spectrum of disease
and the majority of patients have symptoms between these deﬁned
syndromes. The recent observation showing that both the mtDNA
deletion size and heteroplasmy level have a signiﬁcant role in
deﬁning the disease phenotype and clinical progression highlights
the important link with the biochemical defect.Treatments for mtDNA disease
Although the pace of mitochondrial research has increased since
the ﬁrst description of pathogenic mtDNA mutations in the late
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tions, effective treatments have not been developed yet. Treat-
ment guidelines are generally developed around the supportive
management of the diseases rather than their correction, for
further information see: http://www.newcastle-mitochondria.
com/public-patient/patient-care-guidelines/. This is partly due to
the difﬁculty of delivering treatments to mitochondria; however,
as our understanding of mitochondrial transport processes has
increased, so has our ability to target molecules to the matrix.
In order to treat mtDNA disease, mutated genomes must be
prevented from having their pathogenic effects, either by targeted
degradation or prevention of replication [33]. Either of these
paradigms will shift the balance of heteroplasmy, increasing the
amount of wild type mtDNA and correcting the biochemical
deﬁciency. Recent advances in delivering anti-genomic treat-
ments to the mitochondrial matrix of diseased cell lines have
been made, all of which have potential to cure mtDNA disease in
affected individuals (Fig. 2).
Early efforts to alter heteroplasmy used mitochondrially targeted
PNA (peptide nucleic acid) oligomers, DNA with a backbone of
amino glycine residues rather than phosphate ribose groups, to
speciﬁcally bind mutated mtDNA and prevent its replication.
Although this work showed promise in vitro, cell line work was
less successful due to issues with PNA solubility and delivery [33,34].
The ﬁrst such therapy to be successfully explored in cell lines was
matrix delivery of SmaI endonuclease by the addition of mitochon-
dria targeting peptide presequences, small peptides at the
N-terminal which cause nuclear encoded mitochondrial proteins
to be delivered to the organelle. As mentioned previously the
m.8993T4G mutation creates a unique restriction site which is
cleaved by SmaI enzymes, inducing a double strand DNA break [35].
Delivery of this enzyme to mutant cell lines resulted in a complete
depletion of mutated genomes, improving the biochemical defect.
A further advance was the use of Cys2–His2 zinc ﬁnger peptides
(ZFPs)— small protein motifs characterised by ﬁnger like protru-
sions that enable the speciﬁc binding of small, triplet DNA
sequences. These proteins can be designed to recognise any
sequence and, with the addition of nucleases to induce double
stand breaks in the mutated genome, can be used to remove any
disease causing inherited mtDNA mutation. Minczuk et al. have
developed ZFPs that are targeted to mitochondria using the COX
VII targeting sequence [36,37]. The natural ability of ZFPs to
localise to the nucleus meant that the addition of a nuclear
exclusion sequence was also required. The authors designed a ZFP
that recognised and bound the m.8993T4G NARP/Leigh's
syndrome mutation. Once bound, the mutated mtDNA was cut
by two FokI nucleases that dimerised to induce double strand
DNA breaks [36]. This had the effect of causing a stable decline in
the heteroplasmy of patient cell lines over a 30-day period [36].
The ability of ZFPs to recognise any sequence makes them very
attractive as a potential treatment; however the need for a
nuclear exclusion sequence complicates their use.
A further advance in this ﬁeld was the development of TALEs
(Transcription Activator-Like Effectors), a family of proteins which
can bind DNA in a sequence speciﬁc manner [38,39]. As with ZFPs,
TALEs can be modiﬁed to include nucleases and targeting
sequences. They are more amenable for use in mitochondria as
they do not have an innate ability to localise to the nucleus.
Bacman et al. engineered TALEs with FokI nucleases to create
TALENs (TALE nucleases) with mitochondrial targeting sequencesto bind and cleave the 4977 bp “common deletion” breakpoint
(m.8483–13459) in patient derived cell lines [40]. To cut DNA, two
TALENs with FokI nucleases were created: one TALEN was
complementary to the deletion breakpoint, the other to a region
of wild-type mtDNA downstream of the breakpoint. This enabled
the FokI nucleases to be in close proximity to dimerise and be cut
when bound to mutated mtDNA. Wild-type molecules were not
cut as the breakpoint was not present; therefore only one TALEN
bound which was not sufﬁcient cut the DNA as only one FokI was
present. The authors showed a decrease in heteroplasmy from
70% to 30% in cell lines which contained both TALENs, without
affecting the overall copy number of the cells [40].
Although all of these techniques have shown excellent efﬁcacy,
the delivery of the recombinant protein is an issue. However, in
mitochondrial disorders such as LHON, which primarily affects
the eye, transfection may be possible by viral delivery. While the
above approaches show that it is possible to remove mutated
mtDNA in a targeted manner, the approaches are limited by the
lack of efﬁcient delivery mechanisms— something that must be
solved in order to deliver these therapies to all affected tissues, in
particular to neurons and cardiac muscle.Conclusion
The discovery and investigation of pathogenic mtDNA mutations
over last 30 years has highlighted the complex relationship
between mutation and disease. This heterogeneity makes mito-
chondrial diseases one of the most challenging neurometabolic
diseases to study. The unique biology of mitochondria also makes
the development of therapeutics very difﬁcult, and as these two
factors combine, it becomes clear why there have been few
signiﬁcant advances in the treatment of these disorders. However,
recent advances in the development of anti-genomic therapies
have shown that it is possible to directly target the cause of
mtDNA disease – mutations in mtDNA. These developments,
along with recent advances in reproductive options to women
with mtDNA mutations (HFEA review, 2013 – http://www.hfea.
gov.uk/6372.html), should offer hope to the patients affected by
these disorders that with the right delivery mechanisms, we may
one day be able to cure these diseases.Acknowledgments
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